A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

Cited by (366)

Items 101–200 of 366

1. New options in the treatment of respiratory syncytial virus disease
   Asunción Mejías, Octavio Ramilo · 2015 · Journal of Infection
2. Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review
   Yanis Ramdani, Juliette Lamamy, Hervé Watier, Valérie Gouilleux‐Gruart · 2022 · International Journal of Molecular Sciences
3. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life
   Colby A Souders, Stuart Nelson, Yang Wang, Andrew R. Crowley, Mark S. Klempner, William D. Thomas · 2015 · mAbs
4. Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human
   Haraya, Kenta, Tachibana, Tatsuhiko, Nezu, Junichi · 2017 · Drug Metabolism and Pharmacokinetics
5. Microbiome Modulation as a Novel Strategy to Treat and Prevent Respiratory Infections
   Barbara C. Mindt, Antonio DiGiandomenico · 2022 · Antibiotics
6. Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development
   Christophe Dumet, Jérémy Pottier, Valérie Gouilleux‐Gruart, Hervé Watier · 2019 · mAbs
7. The potential of engineered antibodies for HIV-1 therapy and cure
   Marloes Grobben, Richard AL Stuart, Marit J. van Gils · 2019 · Current Opinion in Virology
8. Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia—Implications for Vaccine Design
   Emma Rey-Jurado, Alexis M. Kalergis · 2017 · International Journal of Molecular Sciences
9. Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling
   Deni Hardiansyah, Chee M. Ng · 2018 · mAbs
10. Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults
    Saskia C. van der Boor, Merel J. Smit, Stijn W. van Beek, Jordache Ramjith, Karina Teelen, Marga van de Vegte‐Bolmer, Geert‐Jan van Gemert, Peter Pickkers, Yimin Wu, Emily Locke et al. · 2022 · The Lancet Infectious Diseases
11. New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment
    Lúcio Gama, Richard A. Koup · 2017 · Annual Review of Medicine
12. Anti-bacterial Monoclonal Antibodies
    Eszter Nagy, Gábor Nagy, Christopher Power, Adriana Badarau, Valéria Szijártó · 2017 · Advances in experimental medicine and biology
13. Passive Immunization
    Mark K. Slifka, Ian J. Amanna · 2017 · Elsevier eBooks
14. Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections
    Pardis Mokhtary, Zeinab Pourhashem, Akram Abouie Mehrizi, Claudia Sala, Rino Rappuoli · 2022 · Biomedicines
15. Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
    Karolina Akinosoglou, Emmanouil Angelos Rigopoulos, Georgia D. Kaiafa, Stylianos Daios, Eleni Karlafti, Eleftheria Ztriva, Georgios Polychronopoulos, Charalambos A. Gogos, Christos G. Savopoulos · 2022 · Viruses
16. Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization
    Stian Foss, Algirdas Grevys, Kine Marita Knudsen Sand, Malin Bern, Patricia A. Blundell, Terje Einar Michaelsen, Richard J. Pleass, Inger Sandlie, Jan Terje Andersen · 2015 · Journal of Controlled Release
17. Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody
    Michael S. Piepenbrink, Jun‐Gyu Park, Ashlesha A. Deshpande, Andreas Loos, Chengjin Ye, Madhubanti Basu, Sanghita Sarkar, Ahmed Magdy Khalil, David Chauvin, Jennifer C. Woo et al. · 2022 · PLoS Pathogens
18. Humoral and cellular immunity to RSV in infants, children and adults
    Christopher Green, Charles Sande, Catherine de Lara, Amber Thompson, Laura Silva-Reyes, Federico Napolitano, Angiolo Pierantoni, Stefania Capone, Alessandra Vitelli, Paul Klenerman et al. · 2018 · Vaccine
19. Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
    Alessandro Rocca, Carlotta Biagi, Sara Scarpini, Arianna Dondi, Silvia Vandini, Luca Pierantoni, Marcello Lanari · 2021 · International Journal of Molecular Sciences
20. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models
    Delphine Valente, Christine Mauriac, Thorsten Schmidt, Ingo Focken, Jochen Beninga, Brian C. Mackness, Huawei Qiu, Pascale Vicat, Abdullah Kandira, Katarina Radošević et al. · 2020 · mAbs
21. Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation
    Kenta Haraya, Haruka Tsutsui, Yasunori Komori, Tatsuhiko Tachibana · 2022 · Pharmaceuticals
22. Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering
    Kenta Haraya, Tatsuhiko Tachibana, Tomoyuki Igawa · 2018 · Drug Metabolism and Pharmacokinetics
23. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
    Teresa H. Evering, Kara W Chew, Mark J Giganti, Carlee Moser, Mauricio Pinilla, David Alain Wohl, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Rachel Bender Ignacio et al. · 2023 · Annals of Internal Medicine
24. Systematic Review of the Efficacy and Safety of RSV‐Specific Monoclonal Antibodies and Antivirals in Development
    Andrea T. K. Sevendal, Siobhan M Hurley, Adam William Bartlett, William D. Rawlinson, Gregory J. Walker · 2024 · Reviews in Medical Virology
25. Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases
    Whitney Shatz-Binder, Jeffrey Aaronson, Stefan T. Yohe, Robert F. Kelley, Yogeshvar N. Kalia · 2018 · Expert Opinion on Drug Delivery
26. The long road to protect infants against severe RSV lower respiratory tract illness
    Sofia Jares Baglivo, Fernando P. Polack · 2019 · F1000Research
27. Monoclonal antibodies in breast cancer: A critical appraisal
    Akanksha Behl, Zahoor Ahmad Wani, Nagendra Nath Das, Virinder Singh Parmar, Christophe Len, Shashwat Malhotra, Anil Kumar Chhillar · 2023 · Critical Reviews in Oncology/Hematology
28. Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
    Pablo Forte-Soto, Muna Albayaty, Dennis A. Brooks, Rosalinda H. Arends, John S. Tillinghast, Anastasia A. Aksyuk, Jérôme Bouquet, Cecil Chen, Asfiha Gebre, Robert J Kubiak et al. · 2023 · The Journal of Infectious Diseases
29. AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults
    Yíngyún Caì, Seme Diallo, Kim Rosenthal, Kuishu Ren, Daniel J. Flores, Andrew B. Dippel, Vaheh Oganesyan, Nydia van Dyk, Xiaoru Chen, Erin N. Cantu et al. · 2024 · Science Translational Medicine
30. A potent broad-spectrum neutralizing antibody targeting a conserved region of the prefusion RSV F protein
    Yongpeng Sun, Liqin Liu, Hongsheng Qiang, Hui Sun, Yichao Jiang, Ren Luo, Ze-Min Jiang, Siyu Lei, Li Chen, Yizhen Wang et al. · 2024 · Nature Communications
31. Antibody and antibody derivatives as cancer therapeutics
    Keith J. Arlotta, Shawn C. Owen · 2019 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
32. Aptamers in cancer therapy: problems and new breakthroughs
    Baijiang Jin, Zhukang Guo, Zhu Chen, Hui Chen, Song Li, Yan Deng, Lian Ji Jin, Yuan Liu, Yuanying Zhang, Nongyue He · 2023 · Journal of Materials Chemistry B
33. Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial
    Ghady Haidar, Steven Thomas, Paul Loubet, Ross Ian Baker, Thomas Benfield, Jim B. Boonyaratanakornkit, Sasisopin Kiertiburanakul, Alfred H.J. Kim, Erin E. Longbrake, Jean‐Michel Molina et al. · 2025 · The Lancet Infectious Diseases
34. Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody
    Atsuhiko Maeda, Yuki Iwayanagi, Kenta Haraya, Tatsuhiko Tachibana, Genki Nakamura, Takeru Nambu, Keiko Esaki, Kunihiro Hattori, Tomoyuki Igawa · 2017 · mAbs
35. Antibody Therapy for the Control of Viral Diseases: An Update
    Miriam Dibo, Eduardo Coló Battocchio, Lucas Marcelino dos Santos Souza, Matheus Deroco Veloso da Silva, Bruna Karina Banin Hirata, Milena Menegazzo Miranda-Sapla, Poliana Camila Marinello, Sérgio Paulo Dejato Rocha, Ligia Carla Faccin Galhardi · 2019 · Current Pharmaceutical Biotechnology
36. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody
    Kenta Haraya, Tatsuhiko Tachibana, Masahiko Nanami, Masaki Ishigai · 2014 · Xenobiotica
37. Application of FcRn Binding Assays to Guide mAb Development
    Amita Datta‐Mannan, Victor J. Wroblewski · 2014 · Drug Metabolism and Disposition
38. Plasma and Liver Protein Binding of N-Acetylgalactosamine–Conjugated Small Interfering RNA
    Sara C. Humphreys, Mai B. Thayer, Julie M. Lade, Bin Wu, Kelvin K. C. Sham, Babak Basiri, Yue Hao, Xin Yun Huang, Richard J. Smith, Brooke M. Rock · 2019 · Drug Metabolism and Disposition
39. A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK ‐1654 in healthy Japanese adults
    Yuji Orito, Naoyuki Otani, Yuki Matsumoto, Katsukuni Fujimoto, Nobuyuki Oshima, Brian M. Maas, Luzelena Caro, Antonios O. Aliprantis, Kara S. Cox, Osamu Tokumaru et al. · 2022 · Clinical and Translational Science
40. Global and Local Conformation of Human IgG Antibody Variants Rationalizes Loss of Thermodynamic Stability
    Matthew J. Edgeworth, Jonathan J. Phillips, David C. Lowe, Alistair D. Kippen, Daniel R. Higazi, James H. Scrivens · 2015 · Angewandte Chemie International Edition
41. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys
    Patrick M. Glassman, Yang Chen, Joseph P. Balthasar · 2015 · Journal of Pharmacokinetics and Pharmacodynamics
42. Small Molecules and Antibodies for Zika Therapy
    Xuping Xie, Jing Zou, Chao Shan, Pei‐Yong Shi · 2017 · The Journal of Infectious Diseases
43. Blocking Borrelia burgdorferi transmission from infected ticks to nonhuman primates with a human monoclonal antibody
    Zachary A. Schiller, Michael J. Rudolph, Jacqueline R. Toomey, Monir Ejemel, Alan LaRochelle, Simon A. Davis, Havard S. Lambert, Aurélie Kern, Amanda C. Tardo, Colby A. Souders et al. · 2021 · Journal of Clinical Investigation
44. Next-generation antibody-based therapies in neurology
    Tobias Ruck, Falk Nimmerjahn, Heinz Wiendl, Jan D. Lünemann · 2021 · Brain
45. Anti-PCSK9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity–Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor–Binding Enhancement
    Kirk R. Henne, Brandon L. Ason, Monique Howard, Wei Wang, Jeonghoon Sun, Jared Higbee, Jie Tang, Katherine C Matsuda, Ren Xu, Lei Zhou et al. · 2015 · Journal of Pharmacology and Experimental Therapeutics
46. Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children
    Joseph B. Domachowske, Ulrika Wählby Hamrén, Irfana Banu, Roberta Baronio, Bhanu Basavaraju, Anthonet Lombard Koen, Amanda Jane Leach, Vaishali S. Mankad, Pia S. Pannaraj, Pere Soler‐Palacín et al. · 2024 · PEDIATRICS
47. Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data
    Xiangdan Wang, Patrick McKay, Liliana T. Yee, George Dutina, Philip E. Hass, Ihsan Nijem, David Allison, Kyra J. Cowan, Kevin Lin, Valerie E. Quarmby et al. · 2016 · mAbs
48. A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus
    Emma Rey-Jurado, Jorge A. Soto, Nicolás M. S. Gálvez, Alexis M. Kalergis · 2017 · Human Vaccines & Immunotherapeutics
49. Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue
    Qianqian Li, Huan Li, Zhihua Li, Youchun Wang · 2024 · MedComm
50. Development of therapeutic antibodies to G protein-coupled receptors and ion channels: Opportunities, challenges and their therapeutic potential in respiratory diseases
    Julie A. Douthwaite, Donna K. Finch, Tomas Mustelin, Trevor C. I. Wilkinson · 2016 · Pharmacology & Therapeutics
51. Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
    Evi Budo Struble, Jonathan M. O. Rawson, Tzanko S. Stantchev, Dorothy Scott, Marjorie A. Shapiro · 2023 · Pharmaceutics
52. Improving the Pharmacodynamics and In Vivo Activity of ENPP1‐Fc Through Protein and Glycosylation Engineering
    Paul R. Stabach, Kristin Zimmerman, Aaron Adame, Dillon Kavanagh, Christopher T. Saeui, Christian Agatemor, Shawn D. Gray, Wenxiang Cao, Enrique M. De La Cruz, Kevin J. Yarema et al. · 2020 · Clinical and Translational Science
53. Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics
    A. R. Satvik Iyengar, Shreya Gupta, Snehal Sainath Jawalekar, Abhay H. Pande · 2019 · Journal of Pharmacology and Experimental Therapeutics
54. A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
    Fatma Haddad, Ghadeer Dokmak, Rafik Karaman · 2022 · Life
55. Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper
    Karelle Ménochet, Hongbin Yu, Bonnie Wang, Jay Tibbitts, Cheng‐Pang Hsu, Amrita V. Kamath, Wolfgang F. Richter, Andreas Baumann · 2022 · mAbs
56. Towardin vitro-to-in vivotranslation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms
    Claudia A. Castro Jaramillo, Sara Belli, Anne‐Christine Cascais, Sherri Dudal, Martin R. Edelmann, Markus Haak, Marie-Elise Brun, Michael B. Otteneder, Mohammed Ullah, Christoph Funk et al. · 2017 · mAbs
57. Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering
    Johan M. S. van der Schoot, Felix L. Fennemann, Michael Valente, Yusuf Dölen, Iris M. Hagemans, Anouk M. D. Becker, Camille M. Le Gall, Duco van Dalen, Alper Çevirgel, Jaco A. C. van Bruggen et al. · 2019 · Science Advances
58. Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery
    Cláudia Azevedo, Soraia Filipa Tavares Pinto, Sopisa Benjakul, Jeannette Nilsen, Hélder A. Santos, Giovanni Traverso, Jan Terje Andersen, Bruno Filipe Carmelino Cardoso Sarmento · 2021 · Advanced Drug Delivery Reviews
59. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
    Yun Ji, Qi Zhang, Lin Cheng, Jiwan Ge, Ruoke Wang, Mengqi Fang, Eric M. Mucker, Peng Chen, Ji Ma, Rui Zhang et al. · 2022 · Frontiers in Immunology
60. New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV
    Nicolás M. S. Gálvez, Jorge A. Soto, Alexis M. Kalergis · 2017 · International Journal of Molecular Sciences
61. Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies
    Andrew B. Dippel, Austin S. Gallegos, Vineela Aleti, Arnita S. Barnes, Xiaoru Chen, Elizabeth A. Christian, Jared A. Delmar, Qun Du, Reza Esfandiary, Erika Farmer et al. · 2022 · mAbs
62. Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance
    Dennis R. Goulet, Michael J. Watson, Susan H. Tam, Adam Zwolak, Mark L. Chiu, William M. Atkins, Abhinav Nath · 2018 · Drug Metabolism and Disposition
63. Implications of Fc Neonatal Receptor (FcRn) Manipulations for Transplant Immunotherapeutics
    Stanley C. Jordan, Noriko Ammerman, Ashley A. Vo · 2019 · Transplantation
64. Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
    Gjølberg, Torleif Tollefsrud, Mester, Simone, Calamera, Gaia, Telstad, Jenny Skjermo, Sandlie, Inger, Andersen, Jan Terje · 2025 · BioDrugs
65. Leveraging neonatal Fc receptor (FcRn) to enhance antibody transport across the blood brain barrier
    Julien Lafrance‐Vanasse, Shraddha Sadekar, Yanli Yang, Daniela Bumbaca Yadav, William J. Meilandt, Monica K Wetzel-Smith, Hao Cai, Susan Ritger Crowell, Van Nguyen, Vivian Lee et al. · 2025 · Nature Communications
66. Contribution of DNA methylation to the expression of FCGRT in human liver and myocardium
    Romina Beatriz Cejas, Daniel C. J. Ferguson, Adolfo Quiñones‐Lombraña, Jonathan Bard, Javier G. Blanco · 2019 · Scientific Reports
67. Model-informed target product profiles of long-acting-injectables for use as seasonal malaria prevention
    Lydia Burgert, Theresa Reiker, Monica Golumbeanu, Jörg J. Möhrle, Melissa A. Penny · 2022 · PLOS Global Public Health
68. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection
    Blaise Pasquiers, Salih Benamara, Mathieu Felices, Laurent Nguyen, Xavier Declèves · 2022 · International Journal of Molecular Sciences
69. STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary Angioedema
    Vahe Bedian, Nikolaos Biris, Charles A. Omer, Jou-Ku Chung, James R. Fuller, Rafif Dagher, Sachin Chandran, Peter Harwin, Tomas Kiselak, Jonathan D. Violin et al. · 2023 · Journal of Pharmacology and Experimental Therapeutics
70. A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies
    Dongfen Yuan, Frederik Rode, Yanguang Cao · 2018 · The AAPS Journal
71. An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases
    Peipei Liu, Zhongzong Pan, Chunyin Gu, Xiaodan Cao, Xiaowu Liu, Jianjian Zhang, Zheng Xiao, Xueping Wang, Haibing Guo, Dianwen Ju et al. · 2020 · Frontiers in Immunology
72. Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults
    Xiaohua Hao, Zheng Zhang, Ji Ma, Lin Cheng, Yun Ji, Yang Liu, Dong Zhao, Wen Zhang, Chunming Li, Yan Li et al. · 2022 · Frontiers in Pharmacology
73. FcRn regulates antigen presentation in dendritic cells downstream of DEC205-targeted vaccines
    Christophe Macri, Matthew Paxman, Devi Jenika, Xiao Peng Lin, Zahra Elahi, Paul A. Gleeson, Irina Caminschi, Mireille Hanna Lahoud, Jóse A. Villadangos, Justine D. Mintern · 2024 · npj Vaccines
74. Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non‐Ig scaffolds
    Frank-Jan Warnders, Marjolijn N. Lub‐de Hooge, Elisabeth G.E. de Vries, Jos G. W. Kosterink · 2018 · Medicinal Research Reviews
75. Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques
    Yvonne J. Rosenberg, George K. Lewis, David C. Montefiori, Celia C. LaBranche, Mark G. Lewis, Lori A. Urban, Jonathan P. Lees, Lingjun Mao, Xiaoming Jiang · 2019 · PLoS ONE
76. Practical progress towards the development of recombinant antivenoms for snakebite envenoming
    Stefanie K. Menzies, Rohit N. Patel, Stuart Ainsworth · 2025 · Expert Opinion on Drug Discovery
77. Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations
    Kenta Haraya, Tatsuhiko Tachibana · 2022 · BioDrugs
78. Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19
    Lindsay E. Clegg, Oleg Stepanov, Henning Schmidt, Weifeng Tang, Huixia Zhang, Chris Webber, Taylor S. Cohen, Mark Thomas Esser, Mats B. Någård · 2024 · Antimicrobial Agents and Chemotherapy
79. A tripartite cocktail of chimeric monoclonal antibodies passively protects mice against ricin, staphylococcal enterotoxin B and Clostridium perfringens epsilon toxin
    Erin K. Sully, Kevin J. Whaley, Natasha Bohorova, Ognian Bohorov, Charles A. Goodman, Do Kim, Michael H. Pauly, Jesús Velasco, Frederick W. Holtsberg, Eric J. Stavale et al. · 2014 · Toxicon
80. Characterizing the Pharmacokinetics and Biodistribution of Therapeutic Proteins: An Industry White Paper
    Kathryn Ball, Gerard J. M. Bruin, Enrique Escandón, Christoph Funk, Joao N.S. Pereira, Tong‐Yuan Yang, Hongbin Yu · 2022 · Drug Metabolism and Disposition
81. Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation
    Karlijn van der Straten, Marit J. van Gils, Steven W. de Taeye, Godelieve J. de Bree · 2022 · Frontiers in Medical Technology
82. Evaluation of an Fcrn Affinity Chromatographic Method for Igg1-Type Antibodies and Evaluation of Igg Variants
    Florian Cymer, Tilman Schlothauer, Alexander Knaupp, Hermann Beck · 2017 · Bioanalysis
83. Early treatment to prevent progression of SARS-CoV-2 infection
    Myron S. Cohen · 2022 · The Lancet Respiratory Medicine
84. New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus
    Benjamín Diethelm‐Varela, Jorge A. Soto, Claudia A. Riedel, Susan M. Bueno, Alexis M. Kalergis · 2023 · Infection and Drug Resistance
85. A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys
    Ciming Kang, Lin Xia, Yuanzhi Chen, Tianying Zhang, Yiwen Wang, Bing Zhou, Min You, Quan Yuan, Chi‐Meng Tzeng, Zhiqiang An et al. · 2017 · Protein & Cell
86. Chimeric Pneumoviridae fusion proteins as immunogens to induce cross‐neutralizing antibody responses
    Eduardo Olmedillas, Olga Cano, Isidoro Martínez, Daniel Luque, María Carmen Terrón, Jason S. McLellan, José Antonio Melero, Vicente Más · 2017 · EMBO Molecular Medicine
87. A Physiologically‐Based Pharmacokinetic Model for the Prediction of “Half‐Life Extension” and “Catch and Release” Monoclonal Antibody Pharmacokinetics
    Hannah M. Jones, John Tolsma, Zhiwei Zhang, Paul Jasper, Haobin Luo, Gregory L. Weber, Katherine Wright, Joel Bard, Robert D. Bell, Dean Messing et al. · 2020 · CPT Pharmacometrics & Systems Pharmacology
88. Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development
    Bettina Wedi · 2023 · Expert Opinion on Investigational Drugs
89. Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150
    Nithya Thambi, Jia Yao Phuah, Ryan P. Staupe, Lori M Tobias, Yu Cao, Troy W. McKelvey, Radha A. Railkar, Antonios O. Aliprantis, Carmen Sofia Arriola, Brian M. Maas et al. · 2024 · The Journal of Infectious Diseases
90. Novel therapies and vaccines against the human respiratory syncytial virus
    Claudia A. Rivera, Roberto S Gómez, Rodrigo Dı́az, Pablo F. Céspedes, Janyra A. Espinoza, Pablo A. González, Claudia A. Riedel, Susan M. Bueno, Alexis M. Kalergis · 2015 · Expert Opinion on Investigational Drugs
91. Modification of the Fc Region of a Human Anti‐oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half‐life in Cynomolgus Monkeys
    Ivo P. Nnane, Chao Han, Qun Jiao, Susan H. Tam, Hugh M. Davis, Zhenhua Xu · 2017 · Basic & Clinical Pharmacology & Toxicology
92. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis
    Li Li, Zhihai Wu, Min Huan Wu, Xuan Qiu, Yue Wu, Zhihui Kuang, Li Lily Wang, Sun Ta, Yang Liu, Shuai Yi et al. · 2020 · International Immunopharmacology
93. Development and comparison of three cell-based potency assays for anti-respiratory syncytial virus monoclonal antibody
    Dengyun Sun, Amy Han-Ming Hsu, Jorge Quiroz, Xi C. He, Melissa C. Whiteman, Kevin B. Gurney, Shara M. Dellatore · 2021 · Biologicals
94. Fast Characterization of Fc-Containing Proteins by Middle-Down Mass Spectrometry Following IdeS Digestion
    Tao Liu, Huaizu Guo, Lei Zhu, Yingxin Zheng, Jin Xu, Qingcheng Guo, Dapeng Zhang, Weizhu Qian, Jianxin Dai, Yajun Guo et al. · 2016 · Chromatographia
95. Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults
    William R. Lumry, Michele Gunsior, Theodora Cohen, Kristine E. Bernard, Pamela N. Gustafson, Jou-Ku Chung, Christopher J. Morabito · 2025 · Annals of Allergy Asthma & Immunology
96. Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia
    Trang T. Vu, Kyeongmin Kim, Millennium Manna, Justin W. Thomas, Bryan Remaily, Emma J. Montgomery, Travis Costa, Lauren Granchie, Zhiliang Xie, Yizhen Guo et al. · 2023 · Pharmacological Research
97. Overview of prevention and management of acute bronchiolitis due to respiratory syncytial virus
    Marwa Ghazaly, Simon Nadel · 2018 · Expert Review of Anti-infective Therapy
98. Potent universal-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody
    Michael S. Piepenbrink, Jun‐Gyu Park, Ashlesha Desphande, Andreas Loos, Chengjin Ye, Madhubanti Basu, Sanghita Sarkar, David Chauvin, Jennifer C. Woo, Philip Lovalenti et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
99. Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence
    Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori · 2023 · Expert Opinion on Drug Discovery
100. A fluorescent imaging method for analyzing the biodistribution of therapeutic monoclonal antibodies that can distinguish intact antibodies from their breakdown products
     Takuo Suzuki, Chihiro Miyazaki, Akiko Ishii‐Watabe, Minoru Tada, Kumiko Sakai‐Kato, Toru Kawanishi, Nana Kawasaki · 2015 · mAbs